We defined key tumor heterogeneity features, including the presence of mixed KRAS mutations and tertiary lymphoid structures, identifying biomarkers that distinguish the latter from lymph nodes. Lastly, by leveraging patient, cell, and mouse data, we determined which aspects of tumor biology are recapitulated in bulk datasets and reductionist models.

P1, N=64, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed

P1, N=10, Active, not recruiting, University Hospital, Basel, Switzerland | Trial completion date: Jun 2025 --> Jun 2026 | Recruiting --> Active, not recruiting

P2, N=33, Recruiting, City of Hope Medical Center | Trial completion date: Oct 2027 --> Oct 2029 | Trial primary completion date: Oct 2027 --> Oct 2029

Treatment with the Treg-depleting antibody RG6292 suppressed viral transformation in donors that otherwise supported LCL outgrowth, confirming a functional role for Tregs in shaping early EBV infection outcomes. Viral transcript enrichment-seq revealed an upregulation of early lytic and failure to sustain latent gene expression correlating with failure to generate LCL. These findings highlight intact PBMCs as a tractable model to study EBV viral-host interaction in a genetically diverse, human-specific context, and that Tregs play a key determining role in viral transformation.

The competitive receptor ACKR1 was minimally expressed on endothelial cells, consistent with PDAC hypo-vascularity...Differential interactions and the presence of "dominant signaling cell populations " with dominant outgoing signals may underlie the heterogeneity in tumor aggressiveness across these cancers. Comparative scRNA-seq analysis of multiple cancers reveals distinct tumor phenotypes and cell-cell communication patterns, offering insights into the molecular architecture of human solid tumors.

P4, N=20, Terminated, University of Southern California | N=80 --> 20 | Recruiting --> Terminated; Research contract expired

P1, N=30, Completed, University of Chicago | Active, not recruiting --> Completed | N=15 --> 30

These results were maintained even after IPTW adjustment. In SPKT recipients with low immunological risk, basiliximab provides comparable long-term patient and graft outcomes to thymoglobulin while reducing the incidence of opportunistic infections.

P1/2, N=159, Recruiting, Aulos Bioscience, Inc. | Trial completion date: Sep 2025 --> Jun 2026 | Trial primary completion date: Aug 2025 --> Jun 2026

P=N/A, N=75, Active, not recruiting, Mario Negri Institute for Pharmacological Research | Recruiting --> Active, not recruiting

P=N/A, N=220, Not yet recruiting, Huashan hospital affiliated to Fudan university; Huashan hospital affiliated to Fudan university